Modulators of neurodegeneration

By developing benzo[c][1,2,5]thiadiazole compounds as high-affinity binders, the challenges of diagnosis and monitoring of neurodegenerative diseases in existing technologies have been solved. This enables selective binding to α-synuclein fibrils and brain imaging, supporting the development and evaluation of therapeutic drugs.

CN122249208APending Publication Date: 2026-06-19THE GENERAL HOSPITAL CORP +2
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
THE GENERAL HOSPITAL CORP
Filing Date
2024-07-17
Publication Date
2026-06-19

AI Technical Summary

Technical Problem

Existing technologies are insufficient for the effective diagnosis and monitoring of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, and existing neuroimaging methods have limitations.

Method used

Develop benzo[c][1,2,5]thiadiazole compounds as high-affinity binders that can selectively bind to α-synuclein fibrils and cross the blood-brain barrier for use in PET or SPECT imaging, providing diagnostic and monitoring tools.

Benefits of technology

It enables highly selective diagnosis and monitoring of neurodegenerative diseases, supports the development of potential therapeutics and the evaluation of existing therapies, and provides effective brain imaging agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This disclosure provides, for example, benzo[c][1,2,5]thiadiazole compounds and methods for using these compounds, for example, to treat neurodegenerative diseases such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. This disclosure also provides the use of radioactive isotopes, for example... 11 C 18 F or 123 / 125 I. Methods for using radiolabeled benzo[c][1,2,5]thiadiazole compounds and the use of said radiolabeled compounds as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for the diagnosis of neurodegenerative diseases and / or for monitoring the treatment of neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art